Table 1.
Population characteristics
| Overall | Missing | ||
|---|---|---|---|
| n | 1188 | ||
| Sex (%) | Male | 715 (60.2) | 0 |
| Female | 473 (39.8) | ||
| Age (median [IQR]) | 57 [47, 64] | 0 | |
| Disease (%) | Acute myeloid leukemia | 418 (35.2) | 0 |
| MDS or MPN | 286 (24.1) | ||
| Lymphoma/CLL | 231 (19.4) | ||
| ALL | 110 (9.3) | ||
| Plasma cell neoplasm | 111 (9.3) | ||
| Other leukemias | 22 (1.9) | ||
| Non-malignant disorders | 10 (0.8) | ||
| Previous Allo-HCT (%) | 1st allo-HCT | 1141 (96.0) | 0 |
| 2nd allo-HCT | 47 (4.0) | ||
| HCT-CI (median [IQR]) | 2 [1, 4] | 2.1 | |
| HCT year (median [IQR]) | 2015 [2013, 2017] | 0 | |
| Donor type (%) | Matched unrelated | 534 (44.9) | 0 |
| Matched related | 307 (25.8) | ||
| Cord blood | 174 (14.6) | ||
| Mismatched non-haploidentical | 128 (10.8) | ||
| Haploidentical | 45 (3.8) | ||
| Graft source (%) | PBSC T-cell depleted | 498 (41.9) | 0 |
| PBSC unmodified | 428 (36.0) | ||
| Cord blood | 174 (14.6) | ||
| BM unmodified | 88 (7.4) | ||
| Conditioning intensity (%) | Ablative | 806 (67.8) | 0 |
| Reduced Intensity | 275 (23.1) | ||
| Nonmyeloablative | 107 (9.0) | ||
| Conditioning regimens (%) | Bu4/Mel/Flu | 359 (30.2) | 0 |
| Flu/Mel | 233 (19.6) | ||
| Flu/Cy/Tt/TBI400 | 190 (16.0) | ||
| TBI1375/Tt/Cy | 130 (10.9) | ||
| Flu/Bu4 | 87 (7.3) | ||
| Flu/Cy/TBI200 | 107 (9.0) | ||
| Mel/Tt/Flu | 42 (3.5) | ||
| Clo/Tt/Mel | 40 (3.4) | ||
| GVHD prophylaxis (%) | none | 498 (41.9) | 0 |
| MTX-based | 426 (35.9) | ||
| MMF-based | 186 (15.7) | ||
| PTCy-based | 78 (6.6) | ||
| Exposure to antibiotics* up to day 21 (%) | Exposed | 804 (67.7) | 0 |
| Not exposed | 384 (32.3) | ||
The frequency of antibiotic exposure considered any exposure to drugs commonly used in this cohort of treatment of neutropenic fever or for C. difficile diarrhea (oral vancomycin, imipenem-cilastatin, meropenem, piperacillin-tazobactam, clindamycin, and metronidazole) between the first days of conditioning and days 21 post-allo-HCT.
IQR - interquartile range; AML – acute myeloid leukemia; MDS – myelodysplastic syndrome; MPN – myeloproliferative neoplasm; CLL – chronic lymphocytic leukemia; ALL – acute lymphoblastic leukemia; Allo-HCT – allogeneic hematopoietic cell transplantation; HCT-CI - hematopoietic cell transplantation-specific comorbidity index; MTX – Methotrexate; MMF – mycophenolate mofetil; PTCy – post-transplantation Cyclophosphamide.